2023-504178-39-00招募中1 期
Local tolerance and PK/PD assessment of TAR-0520 gel when applied topically in healthy subjects
TARIAN PHARMA1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2023年10月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Janusz Czernielewski
Scientific
TARIAN PHARMA
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1, Open-Label Study to Investigate the TARP-ɣ8 Receptor Occupancy of RAP-219 Using a TARP-γ8 PET Tracer in Healthy Adult ParticipantsEpilepsy2024-512151-21-00Rapport Therapeutics Inc.24
暂停
1 期
评价 PTT-501 单、多次给药的安全性、耐受性和药代动力学特征的 I 期试验CTR2025306584
招募中
2 期
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Intravesical Bacillus Calmette-Guérin who are Ineligible for or Elected Not to Undergo Radical Cystectomy2023-506146-23-00Janssen - Cilag International130
招募中
不适用
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United StatesNCT07309445Janssen Research & Development, LLC150
招募中
2 期
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patients with Prion Disease2023-503355-98-00Ionis Pharmaceuticals Inc.8